Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: A pilot study in Taiwan

Japanese Journal of Clinical Oncology

Volumn 33, Issue 3, 2003, Pages 136-140

  Tai, Cheng Jeng ^a   Liu, Jin Hwang ^a   Chen, Wei Shon ^a   Lin, Jen Kou ^a   Wang, Wei Shu ^a   Yen, Chueh Chuan ^a   Chiou, Tzeon Jye ^a   Chen, Po Min ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Chemotherapy; Irinotecan; Metastatic colorectal cancer; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG MEGADOSE; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER TOXICITY; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PILOT STUDY; QUANTITATIVE ANALYSIS; SALVAGE THERAPY; STOMATITIS; TAIWAN; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; CHEMICALLY INDUCED DISORDER; COLON TUMOR; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; RECTUM TUMOR; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; LEUCOVORIN; LEUKOPENIA; MIDDLE AGED; NAUSEA; PILOT PROJECTS; RECTAL NEOPLASMS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VOMITING, ANTICIPATORY;

EID: 0038519895     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg023     Document Type: Article

References (27)

1. Rothenberg ML. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol 1998;25:39-46.
2. Douglass HO Jr, Lavin PT, Woll J, Conroy JF, Carbone P. Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2′-deoxythioguanosine or with oral 3-(4-methylcyclohexyl)-1-(2-chlorethyl)-1-nitrosourea: A phase II-III study of the Eastern Cooperative Oncology Group (EST 4273). Cancer 1978;42:2538-45.
3. Porschen R, Bermann A, Loffler T, Haack G, Rettig K, Anger Y, et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: Results of the trial adjCCA-01. J Clin Oncol 2001;19:1787-94.
4. Wein A, Riedel C, Bruckl W, Kastl S, Reingruber B, Hohenberger W, et al. Weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with folinic acid (FA) in adjuvant therapy of colon cancer. Z Gastroenterol 2001;39:153-6.
5. Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 1998;34:1871-5.
6. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995;13:210-21.
7. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998;16:2739-44.
8. Bleiberg H. Oxaliplatin (L-OHP): A new reality in colorectal cancer. Br J Cancer 1998;77(Suppl 4):1-3.
9. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998;25:4-12.
10. de Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-9.
11. Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluorouracil: Clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998;25: 32-9.
12. Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999;17:2901-8.
13. de Gramont A, Louvet C, Andre T, Tournigand C, Krulik M. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: Evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer 1998;34:619-26.
14. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-7.
15. Ducreux M, Louvet C, Bekradda M, Cvitkovic E. Oxaliplatin for the treatment of advanced colorectal cancer: Future directions. Semin Oncol 1998; 25:47-53.
16. Wiseman LR, Adkins JC, Plosker GL, Goa KL. Oxaliplatin: A review of its use in the management of metastatic colorectal cancer. Drugs Aging 1999; 14:459-75.
17. Chabot GG. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother Pharmacol 1995;36:463-72.
18. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 1994;54:3723-5.
19. Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995;87:1876-83.
20. Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995;31A:1283-7.
21. de Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994;54:4347-54.
22. O'Connell MJ. Irinotecan for colorectal cancer: A small step forward. Lancet 1998;352:1402.
23. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-23.
24. Cunningham D, Glimelius B. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 1999;26:6-12.
25. Cersosimo RJ. Irinotecan: A new antineoplastic agent for the management of colorectal cancer. Ann Pharmacother 1998;32:1324-33.
26. Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment. J Clin Oncol 1998;16:2745-51.
27. Christophe T, Christophe L, Emmanuel Q, Thierry A, Gerard L, Michel F, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 2001;20:124a (abstr 494).